There has been considerable progress in research on immune checkpoint therapy, programmed cell death protein (PD-1), and PD-L1 immune checkpoint inhibitors (ICIs), with these therapeutic strategies showing a durable response in advanced BLCA patients (Koshkin and Grivas, 2018). Here, PDCD1 is linked to bladder transitional cell carcinoma.